SCHEMBL1017757

SCHEMBL1017757

CCCOCCNc1ccc2c(n1)CCN(CC(=O)N1CCN(C3CCC3)CC1)C2

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 3/20 0.35
CDK4 P11802 8/20 0.35
CDK2 P24941 5/20 0.35
CDK6 Q00534 5/20 0.35
PARP1 P09874 1/20 0.34
CDK1 P06493 4/20 0.33
CCNB1 P14635 2/20 0.33
CCNE1 P24864 2/20 0.33
FLT3 P36888 1/20 0.33
MTNR1B P49286 3/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 2/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
CDK7 P50613 2/20 0.32
CDK9 P50750 2/20 0.32
HRH3 Q9Y5N1 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1017442 0.94 ADRA1A (0.35) ADRA1ACDK4CDK2CDK6PARP1
SCHEMBL14420758 0.92 CDK4 (0.35) ADRA1ACDK4CDK2CDK6PARP1
SCHEMBL1018492 0.91 ADRA1A (0.43) ADRA1ACDK4CDK2CDK6PARP1
SCHEMBL1015014 0.89 ADRA1A (0.35) ADRA1ACDK4CDK2CDK6PARP1
SCHEMBL1016337 0.87 ADRA1A (0.39) ADRA1ACDK4CDK2CDK6PARP1
SCHEMBL12953864 0.87 PARP1 (0.37) CDK4CDK2CDK6PARP1CDK1
SCHEMBL1018540 0.85 CDK4 (0.37) CDK4CDK2CDK6PARP1CDK1
SCHEMBL1017817 0.84 CDK4 (0.36) CDK4CDK2CDK6PARP1CDK1
SCHEMBL1016696 0.84 CDK4 (0.36) CDK4CDK2CDK6PARP1CDK1
SCHEMBL1016650 0.83 NPY5R (0.38) CDK4CDK2CDK6PARP1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ADRA1A 381/4885CDK4 2953/4885CDK2 1752/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ADRA1A 381/4885CDK4 2953/4885CDK2 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.